TREA

97376275 - KD PHARMA

Follow

Information

  • Trademark
  • 97376275
  • Serial Number
    97376275
  • Registration Number
    7593034
  • Filing Date
    April 22, 2022
    2 years ago
  • Registration Date
    December 10, 2024
    a month ago
  • Transaction Date
    December 10, 2024
    a month ago
  • Status Date
    December 10, 2024
    a month ago
  • Published for Opposition Date
    October 08, 2024
    3 months ago
  • Location Date
    December 09, 2024
    a month ago
  • Status Code
    700
  • Current Location
    FILE REPOSITORY (FRANCONIA)
    Employee Name
    KEELEY, ALISON
  • Attorney Docket Number
    1986314
    Attorney Name
    KLAUS P. STOFFEL
  • Owners
Information
Mark Drawing Code
4
Mark Identification
KD PHARMA
Case File Statements
  • GS0291: Oils and fats, namely edible oils and edible fats and oils and fats for food; dietetic oils and fats in the nature of edible oils and fats, not for medical purposes; any cannabis or cannabis derived ingredients in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing containing cannabidiol (CBD)
  • GS0051: Pharmaceutical, medical and veterinary preparations, namely, pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders, pharmaceutical products for the prevention and treatment of cancer, pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines, and chemical reagents for medical or veterinary purposes, chemical reagents for medical or veterinary purposes; sanitary preparations for medical purposes; dietetic foodstuffs and goods for medical or veterinary purposes, namely, dietetic foods and beverages adapted for medical use, dietetic foods adapted for veterinary use, dietetic beverages adapted for veterinary use, and dietetic preparations adapted for medical purposes; food supplements for humans and animals; disinfectants; medicines and natural remedies, namely medicinal oils and antiallergic medicines, medicinal preparations for the treatment of infectious diseases and for use in oncology, medicinal drinks, medicinal preparations for infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders, for the prevention and treatment of cancer, for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria- based diseases, for the treatment of epilepsy, pain, anxiety, depression, sleep disorders, Parkinson's disease, nausea and vomiting, food disorders, arthritis, PTSD, schizophrenia, opioid addiction, alleviate ALS symptoms, multiple sclerosis, and for the treatment of diabetes, natural remedy preparations for the treatment of gastro-intestinal conditions, hormonal and chemical imbalances, and sleep disorders; dietetic preparations, namely Dietetic preparations adapted for medical purposes; food supplements; food for babies; food for infants; infant formula; any cannabis or cannabis derived ingredients in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing containing cannabidiol (CBD)
  • GS0011: Oils and fats, namely, lipids used in the manufacture of cosmetics, beverages, food products, pharmaceuticals and dietary supplements for the manufacture of pharmaceuticals, medical and veterinary preparations, sanitary preparations for medical purposes, dietetic foodstuffs and products for medical or veterinary purposes, food supplements for humans and animals, medicines and natural remedies, dietetic preparations and food supplements and pharmaceutical preparations and substances, dietary supplements and dietetic preparations, food for babies and infants, and for manufacturing beverages for infants and infant formula; any cannabis or cannabis derived ingredients in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing containing cannabidiol (CBD)
  • DS0000: "PHARMA"
Case File Event Statements
  • 4/26/2022 - 2 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 4/27/2022 - 2 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 2/9/2023 - a year ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 2/18/2023 - a year ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 3/1/2023 - a year ago
    5 - ASSIGNED TO EXAMINER Type: DOCK
  • 3/20/2023 - a year ago
    6 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 3/20/2023 - a year ago
    7 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 3/20/2023 - a year ago
    8 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 6/19/2023 - a year ago
    9 - APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Type: XELR
  • 6/19/2023 - a year ago
    10 - APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Type: XELG
  • 9/20/2023 - a year ago
    11 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 9/20/2023 - a year ago
    12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 9/21/2023 - a year ago
    13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 12/4/2023 - a year ago
    14 - FINAL REFUSAL WRITTEN Type: CNFR
  • 12/4/2023 - a year ago
    15 - FINAL REFUSAL E-MAILED Type: GNFR
  • 12/4/2023 - a year ago
    16 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 3/4/2024 - 10 months ago
    17 - APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Type: XELR
  • 3/4/2024 - 10 months ago
    18 - APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Type: XELG
  • 6/4/2024 - 7 months ago
    22 - TEAS REQUEST FOR RECONSIDERATION RECEIVED Type: ERFR
  • 6/4/2024 - 7 months ago
    19 - EXPARTE APPEAL RECEIVED AT TTAB Type: EXAF
  • 6/4/2024 - 7 months ago
    21 - EX PARTE APPEAL-INSTITUTED Type: EXPI
  • 6/4/2024 - 7 months ago
    20 - JURISDICTION RESTORED TO EXAMINING ATTORNEY Type: JURT
  • 7/1/2024 - 6 months ago
    23 - SUBSEQUENT FINAL REFUSAL WRITTEN Type: CFRC
  • 7/1/2024 - 6 months ago
    24 - SUBSEQUENT FINAL EMAILED Type: GNSF
  • 7/1/2024 - 6 months ago
    25 - NOTIFICATION OF SUBSEQUENT FINAL EMAILED Type: GNS1
  • 9/4/2024 - 4 months ago
    27 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 9/4/2024 - 4 months ago
    30 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 9/4/2024 - 4 months ago
    29 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 9/4/2024 - 4 months ago
    28 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 9/4/2024 - 4 months ago
    31 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 9/4/2024 - 4 months ago
    26 - JURISDICTION RESTORED TO EXAMINING ATTORNEY Type: JURT
  • 9/4/2024 - 4 months ago
    32 - EXPARTE APPEAL TERMINATED Type: EXPT
  • 9/18/2024 - 3 months ago
    33 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 10/8/2024 - 3 months ago
    34 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 10/8/2024 - 3 months ago
    35 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 12/10/2024 - a month ago
    36 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 12/10/2024 - a month ago
    37 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC